Last reviewed · How we verify
L-Ornithine (ORNITHINE)
At a glance
| Generic name | ORNITHINE |
|---|---|
| Drug class | Carnitine Analog [EPC] |
| Target | G-protein coupled receptor family C group 6 member A |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Female Facial Hirsutism
Common side effects
Key clinical trials
- The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules (PHASE4)
- Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors (PHASE1,PHASE2)
- Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas (PHASE1,PHASE2)
- Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO) (PHASE1,PHASE2)
- DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma (PHASE2)
- Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas (PHASE1,PHASE2)
- An Intermediate Expanded Use Trial of DFMO
- Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |